3 Mar 2020 Do Analysts Recommend You Should Buy Sarepta Therapeutics, Inc. (SRPT) Stock? Ad. On Monday, shares of Sarepta Therapeutics, Inc. View live SAREPTA THERAPEUTICS INC chart to track its stock's price action. Possible entry on break from symmetrical triangle $134.00 Target price SRPT Sarepta Therapeutics, Inc. daily Stock Chart Feb-19-20 12:31PM, Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What The stocks picks are: PTC Therapeutics (PTCT), Sarepta (SRPT), Ionis Sarepta price target raised to $217 from $211 at Cantor Fitzgerald » 06:56. 02/27/20.
Sarepta Therapeutics, Inc. (SRPT) Analyst Ratings ...
In depth view into SRPT (Sarepta Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. SAREPTA THERAPEUTICS, INC. : SRPT Stock Price | MarketScreener Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of … SRPT Price Target - ETF Channel The median SRPT price target (a different metric than the average or mean) was $188.5 as of 2020-03-16, the highest SRPT price target in the range was $260.0 while the lowest SRPT price target in the range was $160.0, with a standard deviation of $26.354. Get the latest Zacks research report on SRPT — FREE
Sarepta Therapeutics, Inc. (SRPT) stock price, quote ...
3 Feb 2020 As is de rigueur in the sector, Sarepta stock responded to the announcement kept his Buy rating on Sarepta, along with a price target of $190. 20 Dec 2019 Baird analyst Brian Skorney raised the price target on Sarepta Therapeutics ( NASDAQ: SRPT) to $192.00 (from $181.00) while maintaining an Stockopedia rates Sarepta Therapeutics Inc as a Adventurous Momentum Trap . 15 brokers rate StockRank™ · StockReport™ Price Target: ( below Price). 28 Jun 2019 Wall Street analysts are more bullish on Sarepta Therapeutics Inc. and its market- leading gene therapy for Duchenne muscular dystrophy after 20 Aug 2019 Sarepta's first move after its golodirsen rejection will be to negotiate a ISI analysts consider the “major valuation driver of [Sarepta] stock.”
Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT ...
Apr 06, 2016 · Sarepta Therapeutics (SRPT) stock is gaining on Wednesday as Oppenheimer raised its price target on the stock in anticipation of a positive outcome for its eteplirsen drug. Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to ... Sarepta Therapeutics (NASDAQ:SRPT) had its target price lowered by equities research analysts at JPMorgan Chase & Co. from $172.00 to $160.00 in a research note issued on Friday, BenzingaRatingsTable reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 52.60% […]
Messer kept his buy rating on SRPT stock, and raised his price target to 182 from 170. Sarepta has said Vyondys 53 will be priced on parity with Exondys 51, its predecessor, Messer said. The price
This Analyst Thinks Sarepta (SRPT) Stock Can Go to $267 Jun 19, 2018 · Notably, H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta shares, while nearly tripling the price target to $267 (from $96), which implies an upside of 86% from Sarepta Therapeutics Inc.'s Price Target ... - Stock Research It's been a rough 12 months for Sarepta Therapeutics, and it got even rougher on Monday following a substantial price target cut from a Wall Street firm. Find out whether this price cut is SRPT - Sarepta Therapeutics, Inc. Summary, Stock Quote and ... Jan 01, 2010 · Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and
Messer kept his buy rating on SRPT stock, and raised his price target to 182 from 170. Sarepta has said Vyondys 53 will be priced on parity with Exondys 51, its predecessor, Messer said. The price Sarepta Therapeutics (NASDAQ:SRPT) Receives “Buy” Rating ... Sarepta Therapeutics (NASDAQ:SRPT) ‘s stock had its “buy” rating restated by research analysts at Nomura in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They currently have a $230.00 target price on the biotechnology company’s stock. Nomura’s price objective points to a potential upside of 92.36% from the company’s current price.